Abstract
AbstractThe pathological assessment of cystectomy specimens is important for accurate prognostic information and to inform adjuvant therapy decisions. However, there is limited evidence regarding the best approach to fixation, dissection, block selection and microscopic assessment of cystectomies. We report the results of an international survey of 212 pathologists and their approach to cystectomy pathology. There is variation at all stages of the specimen journey including in fixation and dissection techniques, and in the approach to evaluating residual tumour. This is particularly evident in the post-neoadjuvant chemotherapy setting where there is variable use of response scoring systems and differing approaches to sampling. We also find variation in the use of digital and molecular pathology in cystectomy specimens. Finally, we have suggested areas for future research in cystectomy pathological assessment.
Funder
National Institute for Health and Care Research
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Witjes J, Bruins HM, R C, Cathomas R, Comperat E, Efstathiou JA, et al (2024) EAU guidelines on muscle-invasive and metastatic bladder cancer. European association of urology. https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer
2. Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (2022) National institute for health and care excellence. https://www.nice.org.uk/guidance/TA817
3. Douglawi A, Ghoreifi A, Lee R, Ladi-Seyedian S-S, Alsyouf M, Ahmadi H et al (2023) Recurrence patterns in bladder cancer patients with no residual disease (pT0N0) at radical cystectomy: a 20-year experience. Urol Oncol: Semin Original Inv 41(2):107.e9-107.e14
4. Fleischmann A, Thalmann GN, Perren A, Seiler R (2014) Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival. Am J Surg Pathol 38(3):325–332
5. Voskuilen CS, Oo HZ, Genitsch V, Smit LA, Vidal A, Meneses M et al (2019) Multicenter validation of histopathologic tumor regression grade after neoadjuvant chemotherapy in muscle-invasive bladder carcinoma. Am J Surg Pathol 43(12):1600–1610